Literature DB >> 33669769

ApoB-Specific CD4+ T Cells in Mouse and Human Atherosclerosis.

Timoteo Marchini1,2,3, Sophie Hansen1,2, Dennis Wolf1,2.   

Abstract

Atherosclerosis is a chronic inflammatory condition of the arterial wall that leads to the formation of vessel-occluding plaques within the subintimal space of middle-sized and larger arteries. While traditionally understood as a myeloid-driven lipid-storage disease, growing evidence suggests that the accumulation of low-density lipoprotein cholesterol (LDL-C) ignites an autoimmune response with CD4+ T-helper (TH) cells that recognize self-peptides from Apolipoprotein B (ApoB), the core protein of LDL-C. These autoreactive CD4+ T cells home to the atherosclerotic plaque, clonally expand, instruct other cells in the plaque, and induce clinical plaque instability. Recent developments in detecting antigen-specific cells at the single cell level have demonstrated that ApoB-reactive CD4+ T cells exist in humans and mice. Their phenotypes and functions deviate from classical immunological concepts of distinct and terminally differentiated TH immunity. Instead, ApoB-specific CD4+ T cells have a highly plastic phenotype, can acquire several, partially opposing and mixed transcriptional programs simultaneously, and transit from one TH subset into another over time. In this review, we highlight adaptive immune mechanisms in atherosclerosis with a focus on CD4+ T cells, introduce novel technologies to detect ApoB-specific CD4+ T cells at the single cell level, and discuss the potential impact of ApoB-driven autoimmunity in atherosclerosis.

Entities:  

Keywords:  LDL; T cells; apolipoprotein B; atherosclerosis; autoimmunity; immunity

Year:  2021        PMID: 33669769     DOI: 10.3390/cells10020446

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  10 in total

1.  Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B.

Authors:  Payel Roy; John Sidney; Cecilia S Lindestam Arlehamn; Elizabeth Phillips; Simon Mallal; Sujit Silas Armstrong Suthahar; Monica Billitti; Paul Rubiro; Daniel Marrama; Fabrizio Drago; Jenifer Vallejo; Vasantika Suryawanshi; Marco Orecchioni; Jeffrey Makings; Paul J Kim; Coleen A McNamara; Bjoern Peters; Alessandro Sette; Klaus Ley
Journal:  Circ Res       Date:  2022-06-29       Impact factor: 23.213

2.  Increased Level of Tim-3+PD-1+CD4+T Cells With Altered Function Might Be Associated With Lower Extremity Arteriosclerosis Obliterans.

Authors:  Liyuan Cui; Lanting Chen; Yuxin Dai; JingMin Ou; Mingke Qiu; Songcun Wang
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

3.  Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease.

Authors:  Timoteo Marchini; Sara Malchow; Lourdes Caceres; Abed Al Hadi El Rabih; Sophie Hansen; Timothy Mwinyella; Lisa Spiga; Sven Piepenburg; Hauke Horstmann; Tijani Olawale; Xiaowei Li; Lucia Sol Mitre; Mark Colin Gissler; Heiko Bugger; Andreas Zirlik; Timo Heidt; Ingo Hilgendorf; Peter Stachon; Constantin von Zur Muehlen; Christoph Bode; Dennis Wolf
Journal:  Front Cardiovasc Med       Date:  2022-04-11

Review 4.  How the immune system shapes atherosclerosis: roles of innate and adaptive immunity.

Authors:  Payel Roy; Marco Orecchioni; Klaus Ley
Journal:  Nat Rev Immunol       Date:  2021-08-13       Impact factor: 108.555

Review 5.  The Role of Tumor Necrosis Factor Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis.

Authors:  Mark Colin Gissler; Peter Stachon; Dennis Wolf; Timoteo Marchini
Journal:  Front Cardiovasc Med       Date:  2022-02-17

Review 6.  Crosstalk between dendritic cells and T lymphocytes during atherogenesis: Focus on antigen presentation and break of tolerance.

Authors:  Rossella Bellini; Fabrizia Bonacina; Giuseppe Danilo Norata
Journal:  Front Cardiovasc Med       Date:  2022-07-28

Review 7.  The role of immune checkpoints in cardiovascular disease.

Authors:  Laura I Yousif; Anniek A Tanja; Rudolf A de Boer; Arco J Teske; Wouter C Meijers
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

8.  Inflammation and Atherosclerosis.

Authors:  Klaus Ley
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

9.  Modulating Autoimmunity against LDL: Development of a Vaccine against Atherosclerosis.

Authors:  Timoteo Marchini; Tijani Abogunloko; Dennis Wolf
Journal:  Hamostaseologie       Date:  2021-12-23       Impact factor: 1.778

Review 10.  Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis.

Authors:  Bogdan Batko
Journal:  J Clin Med       Date:  2021-12-17       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.